Available pharmacological treatments for anorexia nervosa

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 11, 2004, Pages 2287-2292

  Powers, Pauline S ^a   Santana, Carlos ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Anorexia nervosa; Antipsychotics; Psychosis

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; APPETITE STIMULANT; ARIPIPRAZOLE; CANNABIS; CITALOPRAM; CLOMIPRAMINE; CYPROHEPTADINE; FLUOXETINE; HALOPERIDOL; LITHIUM; MEGESTROL; NEUROLEPTIC AGENT; OLANZAPINE; OXANDROLONE; PH 284; QUETIAPINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VOMEROPHERIN; ZIPRASIDONE;

ANOREXIA NERVOSA; ANXIETY DISORDER; BODY IMAGE; BODY WEIGHT; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROPSYCHOLOGY; OBSESSIVE COMPULSIVE DISORDER; PSYCHOSIS; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ANOREXIA NERVOSA; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; APPETITE STIMULANTS; FEMALE; HUMANS;

EID: 8544241774     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.11.2287     Document Type: Review

References (40)

1. HOEK WH, VAN HOEKEN D: Review of the prevalence and incidence of eating disorders. Int. J. Eat. Disord. (2003) 34:383-396.
2. ROBINS LN, HELZER YE, WEISSMANN NM et al.: Lifetime prevalence of psychiatric disorders in three communities. Arch. Gen. Psychiatry 41:949-967 (1984).
3. MILOS G, SPINDLER A, SCHNYDER U, MARTZ J, HOEK HW, WILLI J: Incidence of severe anorexia nervosa in Switzerland: 40 years of development. Int. J. Eat. Disord. 35:250-258 (2004).
4. SULLIVAN PF: Mortality in anorexia nervosa. Am. J. Psychiatry (1995) 152:1073-1074.
5. THEANDER S: Anorexia nervosa. A psychiatric investigation of 94 female patients. Acta Psychiatr. Scand. (1970) 214 Suppl.):1-194.
6. O'BRIEN KM, VINCENT NK: Psychiatric comorbidity in anorexia and bulimia nervosa: nature, prevalence, and causal relationship. Clin. Psychol. Rev. 23:57-7a4 (2003).
7. MILOS GF, SPINDLER AM, BUDDENBERG C, CRAMERI A: Axes I and II comorbidity and treatment experiences in eating disorder subjects. Psychother. Pychosom. 72:276-285 (2003).
8. MILOS G, SPINDLER A, RUGGIERO G, KLAGHOFER R, SCHNYDER U: Comorbidity of obsessive-compulsive disorders and duration of eating disorders. Int. J. Eat. Disord. (2002) 31:284-289.
9. HERPERTZ-DAHLMANN B, MULLER B, HERPERTZ S, HEUSSEN N, HEBEBRAND J, REMSCHMIDT H: Prospective 10-year follow-up in adolescent anorexia nervosa - course, outcome, psychiatric comorbidity, and psychosocial adaptation. J. Child Psychol. Psychiatry (2001) 42 603-612.
10. POWERS PS, BANNON Y. Medical comorbidity of anorexia nervosa, bulimia nervosa, and binge eating disorder. In: Clinical Handbook of Eating Disorders. Brewerton TD (Ed.). Marcel Dekker, Inc., New York, USA (2004):231-255.
11. STROBER M, FREEMAN R, MORRELL W: The long-term course of severe anorexia nervosa in adolescents: survival analysis of recovery, relapse, and outcome predictors over 10-15 years in a prospective study. Int. J. Eat. Disord. (1997) 22:339-360.
12. YAGER J, ANDERSEN A, DEVLIN M et al.: American Psychiatric Association Practice Guidelines for the Treatment of Patients with Eating Disorders (Revision). Supplement to the Am. J. Psychiatry (2000)157(Suppl.):1.
13. BARAN SA, WELTZIN TE, KAYE WG: Low discharge weight and outcome in anorexia nervosa. Am. J. Psychiatry (1995) 152 1070-1072.
14. FICHTER MM, QUADFLIEG N: Six-year course and outcome of anorexia nervosa. Int. J. Eat. Disord. (1999) 26:359-385.
15. KNIGHT JC, LITTON SC: Psychological testing and eating disorders. In: Current Treatment of Anorexia Nervosa and Bulimia. Powers PS, Fernandez RC (Eds), S. Karger, New York, USA (1984):241-264.
16. POWERS PS, SANTANA CA, BANNON YS: Olanzapine in the treatment of anorexia nervosa: an open label trial. Int. J. Eat. Disord. (2002) 32:146-154.
17. SIMPSON H, BANNON Y, MCCORMICK T, POWERS P: Anorexia nervosa and psychosis. Poster presentation at Research Day, University of South Florida, College of Medicine, April (2004).
18. OHRMANN P, KERSTING A, SUSLOW T et al.: Proton magnetic resonance spectroscopy in anorexia nervosa: correlations with cognition. Neuroreport(2004) 15:549-553.
19. MOSER DJ, BENJAMIN ML, BAYLESS JD et al.: Neuropsychological functioning pretreatment and posttreatment in an inpatient eating disorders program. Int. J. Eat. Disord. (2003) 33:64-70.
20. MCDOWELL BD, MOSER DJ, FERNEYHOUGH K, BOWERS WA, ANDERSEN AE, PAULSEN JS: Cognitive impairment in anorexia nervosa is not due to depressed mood. Int. J. Eat. Disord. (2003) 33:351-355.
21. VELLIGAN DI, MILLER AL: Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J. Clin. Psychiatry (1999) 60 Suppl. 23):25-28.
22. KEREM NC, KATZMAN DK; Brain structure and function in adolescents with anorexia nervosa. Adolesc. Med. (2003) 14: 09-118.
23. PEARLSON GD, MARSH L: Structural brain imaging in schizophrenia: a selective review. Biol. Psychiatry (1999) 46 627-649.
24. KIRALY SJ, ANCILL RJ, DIMITROVA G: The relationship of endogenous cortisol to psychiatric disorder: a review. Can. J. Psychiatry (1997) 42:415-420.
25. HALMI KA, ECKERT E, LADU TJ, COHEN J: Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Arch. Gen. Psychiatry (1986) 43:177-181.
26. SIMMONS SF, WALKER KA, OSTERWEIL D: The effect of megestrol acetate on oral food and fluid intake in nursing home residents: a pilot study. J. Am. Med. Dir. Assoc. (2004) 5:24-30.
27. ATTIA E, HAIMAN C, WALSH BT, FLATER SR: Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am. J. Psychiatry (1998) 155:548-551.
28. DELGADO PL, MILLER HL, SALOMON RM et al.: Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol. Psychiatry 46 212-220.
29. PALLANTI S, QUERCIOLI L, RAMACCIOTTI A: Citalopram in anorexia nervosa. Eat. Weight Disord. (1997) 2:216-221.
30. FASSINO S, LEOMBRUNI P, DAGA G et al.: Efficacy of citalopram in anorexia nervosa: a pilot study. Eur. Neuropsychopharmacol. (2002) 12:453-459.
31. CALANDRA C, GULINO V, INSENA L, GIUFFRIDA A: The use of citalopram in an integrated approach to the treatment of eating disorders: an open study. Eat. Weight Disord. (1999) 4 207-210.
32. KAYE WH, NAGATA T, WELTZIN TE et al.: Double-blind placebo-controlled administration of fluoxetine in restricting- and retstricting-purging-type anorexia nervosa. Biol. Psychiatry (2001) 49:644-652.
33. VANDEREYCKEN W: Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br. J. Psychiatry (1984) 144:288-292.
34. RUGGIERO GM, LAINI V, MAURI MC et al.: A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog. Neuropsychopharmacol. Biol. Psychiatry (2001) 25:1049-1059.
35. CASSANO GB, MINIATI M, PINI S et al.: Six-month open trial of halopereidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int. J. Eat. Disord. (2003) 33:172-177.
36. POWERS PS, BANNON Y, EUBANKS R, MCCORMICK T: Anorexia nervosa and quetiapine: effect on weight and psychopathology. Presented at American Psychiatric Association Annual Meeting. New York, USA, April (2004).
37. NEWMAN-TOKER J: Risperidone in anorexia nervosa. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39:941-942.
38. FISMAN S, STEELE M, SHORT J, BYRNE T, LAVALLEE C: Case study: anorexia nervosa and autistic disorder in an adolescent girl. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:937-940.
39. HORNE RL, FERGUSON JM, POPE HG Jr et al.: Treatment of bulimia with bupropion: a multicenter controlled trial. J. Clin. Psychiatry (1988) 49:262-266.
40. GROSS HA, EBERT MH, FADEN VB, GOLDBERG SC, NEE LE, KAYE WG: A double-blind controlled trial of lithium carbonate in primary anorexia nervosa. J. Clin. Pychopharmacol. (1981) 1:376-381.